Concepedia

Timil H. Patel

TH

Statistics

Publications

2

Citations

106

H-Index

2

Active since

2022

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Timil H. Patel is an author at United States Food and Drug Administration specializing in pathology, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2022–2023

2

Publications

2

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Timil H. Patel, Jamie R. Brewer, Jiaxin Fan et al. · Clinical Cancer Research · 2023 · 57 citations · Full text

, , +16

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Timil H. Patel, Leigh Marcus, M. Naomi Horiba et al. · Clinical Cancer Research · 2022 · 49 citations · Full text

1–2 of 2